Tagged Articles

exenatide 24 articles

Study raises concerns about class of type 2 diabetes drugs

A class of type 2 diabetes drugs used to reduce blood sugar levels may actually promote the release of sugars into the blood, according to a paper published in the Journal of Biological Chemistry. The class of drugs is known as GLP-1 agonists, which includes the brand names Byetta (exenatide) and Victoza (liraglutide), which were made available in the United States in 2005 and 2010, respectively. According to Doctor Tipster, GLP-1 agonists work by imitating the effects of a naturally occurring hormone, called a glucagon-like peptide. This regulates blood sugar levels by stimulating the release of insulin and by inhibiting ... Read More

Newer diabetes drugs linked to acute pancreatitis

Diabetics treated with a newer classes of diabetes drugs have double the risk of being hospitalized with acute pancreatitis, according to a study published in JAMA Internal Medicine. The drug class, known as incretin mimetics, which includes the subclass GLP-1 drugs, include the brand names Januvia (sitagliptin) and Byetta (exenatide). Researchers with Johns Hopkins University School of Medicine in Baltimore found that the drugs contribute to the formation of lesions in the pancreas and an increase in the number of ducts within it, which adds to the frequency and severity of inflammation. Drug regulators were aware of this possibility when ... Read More

Novo Nordisk becomes top diabetes drug seller with Victoza

Danish drug company Novo Nordisk has become the top seller of diabetes medications thanks to its blockbuster type 2 diabetes treatment Victoza (liraglutide), which brought in a whopping $2 billion in sales, up 15 percent over last year. Novo Nordisk displaced Sanofi, which sells numerous insulin products including Lantus, insulin-delivery devices as well as the diabetes drugs Lyxumia (lixisenatide) and Amaryl/Amarel (glimepiride). Victoza was approved by the Food and Drug Administration (FDA) in 2010 and became one of the newer members of a new class of diabetes medications known as incretin mimetics. Other drugs in this class include Byetta/Bydureon (exenatide) ... Read More

New black box warnings added to type 2 diabetes drugs

The safety labels of four type 2 diabetes drugs have been updated to include new black box warnings for thyroid cancer, according to the Food and Drug Administration (FDA). The new warnings were added to Bydureon (exenatide extended-release) injection, Tanzeum (albiglutide) injection, Trulicity (dulaglutide) injection, and Victoza (liraglutide) injection. All the drugs are in a class of diabetes medications known as incretin mimetics. The warning informs physicians and patients that the drugs cause an increased incidence in thyroid C-cell tumors in laboratory rats compared to ones who were not treated with the drugs. The warnings explain that it is unknown ... Read More

Trials underway on experimental diabetes drug

Novo Nordisk’s new oral diabetes drug is proving to be just as effective as its injectable counterpart in clinical studies. The drug, known as OG217SC, is an oral version of the company’s experimental weekly injectable medication semaglutide, from a class of type 2 diabetes drugs known as glucagon-like peptide-1 receptor agonist, or GLP-1 drugs. The drugs work by promoting the body’s natural production of insulin, which not only helps manage insulin levels but also can with weight loss. Weight gain is a contributing factor in type 2 diabetes and many diabetic patients are encouraged to lose weight by following a ... Read More

Lawsuits claim type 2 diabetes drugs caused pancreatic cancer

Ann Falcone of Staten Island, NY is suing two different drug companies alleging their type 2 diabetes treatments caused her to develop pancreatic cancer. Falcone claims she began taking Januvia (sitagliptin) in July 2009 to help control her blood sugar levels. Januvia is a oral antihyperglycemic drug known as a dipeptiidyl peptidase-4, or DPP-4, inhibitor. In May 2011, her doctor also prescribed Victoza (liraglutide), an injectable long-acting glucagon-like peptide-1 agonist, or GLP-1 agonist. Both drugs are in a class of type 2 diabetes medications known as incretin mimetics. But a year after starting Victoza, Falcone was diagnosed with pancreatic cancer. It ... Read More

Top best-selling Type 2 diabetes drugs linked to cancer

Nearly half of the top-selling Type 2 diabetes drugs come from a class of drugs known as incretin mimetics. They have been linked to a painful inflammation of the pancreas called acute pancreatitis, and an increased risk of pancreatic cancer. The list, compiled by Genetic Engineering & Biotechnology News, ranks FDA-approved type 2 diabetes drugs based on sales for the year 2013. Drugs not included in the list include those whose sales figures were withheld, such as Johnson & Johnson’s Invokana (canagliflozin), as well as the several treatments approved during 2014, such as Boehringer Ingelheim’s Jardiance (empagliflozin), Eli Lilly’s Trulicity (dulaglutuide) ... Read More

Long-term pancreatic cancer risks with class of type 2 diabetes drugs still unknown

Drugs in a class of Type 2 diabetes medications known as DPP-4 inhibitors may not increase the short-term risk of pancreatic cancer, but the long-term risks are still unknown, according to a new study published in the journal Diabetes, Obesity and Metabolism. The study was conducted by researchers with the University of North Carolina (UNC) Gillings School of Global Public Health and the UNC School of medicine, and focused on pancreatic cancer risks with DPP-4 inhibitors such as Januvia and Janumet (sitagliptin), and Tradjenta (linagliptin). DPP-4 inhibitors were first marketed in the United States in 2006 and have since become ... Read More

Type 2 diabetes drug adds new warning for serious injection site reactions

New information has been added to the safety label of the injectable type 2 diabetes drug Bydureon to include a new warning that some people using the medication have experienced serious injection-site reactions, some of which have required surgical intervention. The new Injection-Site Reaction information was added to both the Warnings & Precautions and the Adverse Events sections of the medication, and new information was added to the patient counseling information and medication guide. Injection-site reactions reported include abscess, cellutitis and necrosis, with or without bumps, or nodules. Patients are advised to contact their health care provider immediately if they experience ... Read More

Participants sought to test long-term effects of popular type 2 diabetes drugs

Researchers at Washington University School of Medicine in St. Louis are seeking volunteers to participate in a study comparing the long-term risks and benefits of four widely prescribed diabetes drugs. The medications will be given in combination with the widely used metformin. The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study will span five years, during which time researchers will evaluate how the drugs affect blood sugar levels, diabetes complications and quality of life. Each drug’s side effects will also be noted. The research team also aims to examine individual factors associated with better or worse response to ... Read More